About AnaCipher CRO
AnaCipher CRO is a publicly listed company based in Hyderabad (India) founded in 2016. It provides clinical research and bioequivalence studies for pharmaceutical partners. It operates on a B2B model in Consumer and Healthcare sectors. The company has 6,460 employees. Its Indian entity Indoco Remedies Limited reported revenue of ₹1,670 Cr. AnaCipher CRO offers products and services including Bioequivalence Studies, Regulatory Services, Medical Writing, and Pharmacovigilance Services. Its focus areas include Regulatory Services, Pharmacovigilance, Compliance Management and Clinical Research. Its competitors include BioAgilytix, Alderley Analytical, Tentamus, Nordic Bioscience and Advion and 5 more; 3 of its 10 listed competitors have raised funding.
Company details
AnaCipher Clinical Research Organization, a division of Indoco Remedies Ltd., specializes in services like bioavailability, bioequivalence studies, regulatory approvals, medical writing, and pharmacovigilance. Based in Hyderabad, India, it supports bio-pharmaceutical companies in drug development through advanced facilities and trained researchers. The organization has executed over 625 studies and maintains strong regulatory compliance, partnering with various pharmaceutical firms to bring therapies to market efficiently.
- Headquarters Hyderabad, India
- Employees 6,460
- Stage Public
- SectorsConsumerHealthcare
- Email••••••••
- Website anaciphercro.com
- Social LinkedIn
- Legal Name Indoco Remedies Limited
- Date of Incorporation 23 Aug, 1947
- Jurisdiction Mumbai, Maharashtra, India
- Market Cap₹2,137 Cr
INDOCO · NSE
- Share Price₹228.90
-1.12% today
- Revenue₹1,845 Cr
FY 2025-26 · +10.8% YoY
- EBITDA₹135 Cr
Margin 7.3%
- Net Profit−₹91.69 Cr
FY 2025-26 · -22.4% YoY
- ROE-10.1%
ROCE 0.8%
- Debt / Equity1.06
Interest cover 1,364.4x
- Employee Count6,460
Associated legal entities of AnaCipher CRO
AnaCipher CRO operates through Indoco Remedies Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Indoco Remedies Limited Listed CIN L85190MH1947PLC005913 | Active | 23 Aug 1947 | Mumbai, Maharashtra | ₹1,670 Cr | 6,460 | 9 | View details |
Products & Services of AnaCipher CRO
AnaCipher CRO offers a comprehensive portfolio of products and services, including Bioequivalence Studies, Regulatory Services, Medical Writing, and Pharmacovigilance Services.
Conducts drug comparison tests for bioavailability in development.
Handles approvals and documentation for drug regulatory processes.
Prepares reports and submissions for clinical research activities.
Manages drug safety and adverse event reporting systems.
Board of directors of Indoco Remedies Limited (AnaCipher CRO)
Indoco Remedies Limited is the primary company behind AnaCipher CRO. The board of Indoco Remedies Limited currently have 7 directors; the longest-serving is Suresh Govind Kare, appointed in 1963. 19 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Suresh Govind Kare DIN 00179220 | Director | 02 Jul 1963 | 63 yrs 3 mo | Indoco Remedies Limited |
| Sundeep Vasant Bambolkar DIN 00176613 | Managing Director | 27 Mar 2004 | 22 yrs 6 mo | Indoco Remedies Limited |
| Aditi Milind Panandikar DIN 00179113 | Managing Director | 27 Mar 2004 | 22 yrs 6 mo | Indoco Remedies Limited |
| Vasudha Vasant Kamat DIN 07500096 | Director | 27 Mar 2020 | 6 yrs 6 mo | Indoco Remedies Limited |
| Abhijit Yashawant Gore DIN 00301688 | Director | 03 Oct 2020 | 6 yrs | Indoco Remedies Limited |
| Satish Madhav Shenoy DIN 00230711 | Director | 01 Apr 2024 | 2 yrs 6 mo | Indoco Remedies Limited |
| Ajay Prasan Mulgaokar DIN 10457626 | Director | 01 Apr 2024 | 2 yrs 6 mo | Indoco Remedies Limited |
IPO & Listings of AnaCipher CRO
AnaCipher CRO is a publicly listed company on the NSE with ticker symbol INDOCO in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNSE: INDOCO
- Listed entityIndoco Remedies Limited
- Exchange sectorPharmaceuticals
Financials of AnaCipher CRO
Exchange-reported figures of Indoco Remedies Limited, the listed company behind AnaCipher CRO (NSE: INDOCO).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,845 | 1,665 | 1,817 | 1,669 | 1,541 | 1,242 | 1,107 |
| Revenue growth | +10.8% | -8.4% | +8.9% | +8.3% | +24.1% | +12.2% | - |
| EBITDA | 135 | 99.26 | 236 | 286 | 327 | 224 | 123 |
| EBITDA margin | +7.3% | +6.0% | +13.0% | +17.2% | +21.3% | +18.1% | +11.1% |
| Profit before tax | (106) | (74.36) | 136 | 193 | 237 | 132 | 28.57 |
| Net profit | (91.69) | (74.94) | 90.51 | 143 | 155 | 93.23 | 24.30 |
| Net profit margin | -5.0% | -4.5% | +5.0% | +8.6% | +10.1% | +7.5% | +2.2% |
| EPS (₹) | (10.31) | (7.99) | 10.68 | 15.44 | 16.80 | 10.10 | 2.62 |
| Balance sheet | |||||||
| Total assets | 2,068 | 2,060 | 1,828 | 1,402 | 1,200 | 1,071 | 977 |
| Net worth | 939 | 1,022 | 1,110 | 1,028 | 905 | 769 | 680 |
| Total debt | 1,090 | 994 | 672 | 333 | 257 | 267 | 262 |
| Cash & bank | 32.99 | 17.08 | 24.32 | 13.34 | 19.77 | 14.34 | 37.93 |
| Net working capital | 672 | 644 | 643 | 562 | 499 | 378 | 269 |
| Cash flow | |||||||
| Cash from operations | 192 | 94.94 | 157 | 179 | 174 | 82.22 | 123 |
| Cash from investing | (102) | (339) | (433) | (208) | (121) | (66.69) | (55.93) |
| Cash from financing | (76.79) | 241 | 280 | 22.80 | (44.37) | (29.87) | (63.95) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 468 | 476 | 445 | 485 | 440 | 390 | 411 | 433 |
| Revenue growth (YoY) | +6.3% | +21.9% | +8.5% | +12.0% | +1.9% | - | - | - |
| Other income | 99.52 | 3.70 | 0.98 | 0.76 | 1.63 | 2.02 | 1.84 | 1.56 |
| EBITDA | 41.02 | 49.71 | 25.36 | 42.52 | 17.53 | (0.78) | 12.03 | 40.25 |
| EBITDA margin | +8.8% | +10.9% | +5.8% | +9.0% | +4.1% | -0.2% | +3.0% | +9.3% |
| Depreciation | 34.53 | 32.49 | 32.01 | 32.25 | 29.70 | 28.78 | 28.72 | 28.82 |
| Interest | 28.29 | 45.92 | 25.64 | 24.56 | 26.12 | 17.98 | 16.11 | 17.83 |
| Profit before tax | 77.72 | (25.00) | (31.31) | (13.53) | (36.66) | (45.52) | (30.96) | (4.84) |
| Tax | 12.28 | (1.32) | (1.86) | (4.32) | (0.31) | (4.18) | (2.56) | 5.17 |
| Net profit | 65.44 | (23.68) | (29.45) | (9.21) | (36.35) | (41.34) | (28.40) | (10.01) |
| EPS (₹) | 7.09 | (2.56) | (3.19) | (1.00) | (3.94) | (4.48) | (3.08) | (1.08) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,686 | 1,518 | 1,791 | 1,667 | 1,540 | 1,240 | 1,106 |
| Revenue growth | +11.1% | -15.2% | +7.5% | +8.3% | +24.1% | +12.1% | - |
| EBITDA | 151 | 128 | 250 | 285 | 327 | 224 | 123 |
| EBITDA margin | +9.0% | +8.4% | +14.0% | +17.1% | +21.2% | +18.0% | +11.2% |
| Profit before tax | (11.46) | (7.36) | 153 | 192 | 236 | 131 | 28.70 |
| Net profit | (3.07) | (10.08) | 108 | 142 | 155 | 92.56 | 24.43 |
| Net profit margin | -0.2% | -0.7% | +6.0% | +8.5% | +10.1% | +7.5% | +2.2% |
| EPS (₹) | (0.61) | (0.95) | 12.65 | 15.34 | 16.77 | 10.03 | 2.63 |
| Balance sheet | |||||||
| Total assets | 1,904 | 1,904 | 1,686 | 1,401 | 1,200 | 1,069 | 978 |
| Net worth | 1,099 | 1,103 | 1,127 | 1,027 | 904 | 769 | 680 |
| Total debt | 760 | 754 | 514 | 333 | 257 | 258 | 262 |
| Cash & bank | 20.00 | 12.03 | 16.94 | 12.40 | 19.21 | 14.05 | 37.65 |
| Net working capital | 654 | 651 | 628 | 559 | 496 | 375 | 267 |
| Cash flow | |||||||
| Cash from operations | 226 | 107 | 177 | 179 | 174 | 82.17 | 123 |
| Cash from investing | (87.38) | (276) | (302) | (209) | (121) | (66.70) | (55.95) |
| Cash from financing | (133) | 169 | 122 | 22.81 | (44.37) | (29.83) | (63.95) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 409 | 449 | 401 | 442 | 394 | 347 | 373 | 397 |
| Revenue growth (YoY) | +3.7% | +29.3% | +7.4% | +11.5% | -1.8% | - | - | - |
| Other income | 102 | 14.03 | 7.17 | 6.54 | 5.58 | 6.50 | 5.25 | 4.20 |
| Total expenses | 367 | 386 | 381 | 389 | 379 | 344 | 353 | 344 |
| EBITDA | 42.21 | 63.03 | 19.89 | 52.86 | 14.82 | 3.46 | 20.14 | 52.87 |
| EBITDA margin | +10.3% | +14.7% | +5.1% | +12.3% | +3.8% | +1.0% | +5.5% | +13.4% |
| Depreciation | 28.05 | 26.71 | 27.36 | 27.63 | 25.20 | 24.88 | 24.75 | 24.92 |
| Interest | 22.75 | 22.73 | 20.15 | 22.01 | 23.61 | 15.98 | 14.00 | 14.77 |
| Profit before tax | 93.22 | 27.62 | (20.45) | 9.76 | (28.41) | (30.90) | (13.36) | 17.38 |
| Tax | 10.90 | 0.27 | (0.45) | (5.29) | (0.34) | (4.66) | (3.13) | 4.59 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 468 | 476 | 445 | 485 | 440 | 390 | 411 | 433 |
| Revenue growth (YoY) | +6.3% | +21.9% | +8.5% | +12.0% | +1.9% | - | - | - |
| Other income | 99.52 | 3.70 | 0.98 | 0.76 | 1.63 | 2.02 | 1.84 | 1.56 |
| EBITDA | 41.02 | 49.71 | 25.36 | 42.52 | 17.53 | (0.78) | 12.03 | 40.25 |
| EBITDA margin | +8.8% | +10.9% | +5.8% | +9.0% | +4.1% | -0.2% | +3.0% | +9.3% |
| Depreciation | 34.53 | 32.49 | 32.01 | 32.25 | 29.70 | 28.78 | 28.72 | 28.82 |
| Interest | 28.29 | 45.92 | 25.64 | 24.56 | 26.12 | 17.98 | 16.11 | 17.83 |
| Profit before tax | 77.72 | (25.00) | (31.31) | (13.53) | (36.66) | (45.52) | (30.96) | (4.84) |
| Tax | 12.28 | (1.32) | (1.86) | (4.32) | (0.31) | (4.18) | (2.56) | 5.17 |
| Net profit | 65.44 | (23.68) | (29.45) | (9.21) | (36.35) | (41.34) | (28.40) | (10.01) |
| EPS (₹) | 7.09 | (2.56) | (3.19) | (1.00) | (3.94) | (4.48) | (3.08) | (1.08) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,845 | 1,665 | 1,817 | 1,669 | 1,541 | 1,242 | 1,107 |
| Revenue growth | +10.8% | -8.4% | +8.9% | +8.3% | +24.1% | +12.2% | - |
| Other income | 6.79 | 6.45 | 29.58 | 2.34 | 2.33 | 3.12 | 2.44 |
| Total expenses | 1,710 | 1,566 | 1,581 | 1,383 | 1,213 | 1,017 | 983 |
| Employee cost | 426 | 394 | 362 | 323 | 296 | 274 | 257 |
| EBITDA | 135 | 99.26 | 236 | 286 | 327 | 224 | 123 |
| EBITDA margin | +7.3% | +6.0% | +13.0% | +17.2% | +21.3% | +18.1% | +11.1% |
| Depreciation | 126 | 114 | 91.87 | 70.61 | 78.96 | 73.13 | 70.82 |
| Interest | 122 | 66.23 | 38.02 | 25.03 | 14.14 | 22.26 | 26.25 |
| Profit before tax | (106) | (74.36) | 136 | 193 | 237 | 132 | 28.57 |
| Tax | (7.81) | 3.58 | 38.79 | 50.55 | 81.77 | 38.95 | 4.46 |
| Net profit | (91.69) | (74.94) | 90.51 | 143 | 155 | 93.23 | 24.30 |
| Net profit margin | -5.0% | -4.5% | +5.0% | +8.6% | +10.1% | +7.5% | +2.2% |
| EPS (₹) | (10.31) | (7.99) | 10.68 | 15.44 | 16.80 | 10.10 | 2.62 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 18.46 | 18.45 | 18.44 | 18.43 | 18.43 | 18.43 | 18.43 |
| Reserves & surplus | 921 | 1,004 | 1,091 | 1,010 | 886 | 751 | 661 |
| Shareholders' funds (net worth) | 939 | 1,022 | 1,110 | 1,028 | 905 | 769 | 680 |
| Minority interest | (7.17) | (3.62) | 0.60 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 866 | 785 | 498 | 267 | 177 | 176 | 194 |
| Unsecured loans | 224 | 208 | 174 | 66.14 | 79.87 | 90.99 | 67.54 |
| Total debt | 1,090 | 994 | 672 | 333 | 257 | 267 | 262 |
| Total liabilities | 2,068 | 2,060 | 1,828 | 1,402 | 1,200 | 1,071 | 977 |
| Assets | |||||||
| Gross block | 2,232 | 1,928 | 1,781 | 1,423 | 1,236 | 1,178 | 1,127 |
| Net block | 1,193 | 997 | 954 | 678 | 555 | 570 | 590 |
| Capital work in progress | 90.01 | 321 | 125 | 114 | 122 | 68.10 | 50.70 |
| Investments | 1.46 | 1.46 | 8.71 | 2.46 | 0.02 | 0.02 | 0.02 |
| Inventories | 405 | 419 | 353 | 326 | 311 | 238 | 208 |
| Sundry debtors | 489 | 352 | 406 | 351 | 297 | 234 | 210 |
| Cash & bank balances | 32.99 | 17.08 | 24.32 | 13.34 | 19.77 | 14.34 | 37.93 |
| Loans & advances | 266 | 212 | 164 | 122 | 146 | 137 | 107 |
| Total current assets | 1,193 | 1,001 | 947 | 813 | 774 | 623 | 563 |
| Total current liabilities | 521 | 357 | 305 | 250 | 275 | 244 | 294 |
| Net working capital | 672 | 644 | 643 | 562 | 499 | 378 | 269 |
| Total assets | 2,068 | 2,060 | 1,828 | 1,402 | 1,200 | 1,071 | 977 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 12.11 | 14.86 | 10.92 | 17.47 | 9.42 | 23.76 | 20.80 |
| Net cash from operating activities | 192 | 94.94 | 157 | 179 | 174 | 82.22 | 123 |
| Net cash from investing activities | (102) | (339) | (433) | (208) | (121) | (66.69) | (55.93) |
| Net cash from financing activities | (76.79) | 241 | 280 | 22.80 | (44.37) | (29.87) | (63.95) |
| Net change in cash | 13.82 | (2.75) | 3.93 | (6.54) | 8.05 | (14.34) | 2.97 |
| Closing cash | 32.99 | 17.08 | 24.32 | 13.34 | 19.77 | 14.34 | 37.93 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.8% | -8.4% | +8.9% | +8.3% | +24.1% | +12.2% | - |
| EBITDA growth | +36.4% | -58.0% | -17.5% | -12.6% | +46.0% | +82.1% | - |
| PBT growth | -43.2% | - | -29.6% | -18.5% | +79.2% | +362.1% | +9998.0% |
| Net income growth | -22.4% | -182.8% | -36.8% | -7.7% | +66.4% | +283.7% | - |
| Revenue CAGR (3Y) | +3.4% | +2.6% | +13.5% | +14.7% | +16.7% | +6.0% | +1.0% |
| EBITDA CAGR (3Y) | -22.1% | -32.8% | +1.7% | +32.4% | +62.3% | +18.5% | -7.7% |
| Profitability & leverage | |||||||
| Net income margin | -5.4% | -4.7% | +5.3% | +8.5% | +10.1% | +7.5% | +2.2% |
| Return on capital employed | +0.8% | -0.4% | +10.8% | +16.7% | +22.1% | +15.1% | +5.6% |
| Return on net worth | -10.1% | -7.3% | +9.1% | +14.7% | +18.5% | +12.9% | +3.6% |
| Debt / equity | 1.06 | 0.78 | 0.47 | 0.30 | 0.31 | 0.36 | 0.42 |
| Long-term debt / equity | 0.63 | 0.48 | 0.28 | 0.16 | 0.13 | 0.14 | 0.17 |
| Interest cover | 1,364.40 | -454.25 | 26.36 | 11.62 | 5.69 | 14.73 | 50.11 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.89 | 0.90 | 1.13 | 1.26 | 1.28 | 1.08 | 1.07 |
| Inventory turnover | 4.48 | 4.31 | 5.35 | 5.24 | 5.62 | 5.57 | 5.65 |
| Debtors turnover | 4.39 | 4.39 | 4.80 | 5.15 | 5.80 | 5.59 | 5.45 |
| EPS (₹) | (10.31) | (7.99) | 10.68 | 15.44 | 16.80 | 10.10 | 2.62 |
| Dividend per share (₹) | 0.20 | 0.20 | 1.50 | 2.25 | 2.25 | 1.50 | 0.30 |
| Book value per share (₹) | 101.76 | 110.79 | 120.40 | 111.58 | 98.17 | 83.45 | 73.75 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 409 | 449 | 401 | 442 | 394 | 347 | 373 | 397 |
| Revenue growth (YoY) | +3.7% | +29.3% | +7.4% | +11.5% | -1.8% | - | - | - |
| Other income | 102 | 14.03 | 7.17 | 6.54 | 5.58 | 6.50 | 5.25 | 4.20 |
| Total expenses | 367 | 386 | 381 | 389 | 379 | 344 | 353 | 344 |
| EBITDA | 42.21 | 63.03 | 19.89 | 52.86 | 14.82 | 3.46 | 20.14 | 52.87 |
| EBITDA margin | +10.3% | +14.7% | +5.1% | +12.3% | +3.8% | +1.0% | +5.5% | +13.4% |
| Depreciation | 28.05 | 26.71 | 27.36 | 27.63 | 25.20 | 24.88 | 24.75 | 24.92 |
| Interest | 22.75 | 22.73 | 20.15 | 22.01 | 23.61 | 15.98 | 14.00 | 14.77 |
| Profit before tax | 93.22 | 27.62 | (20.45) | 9.76 | (28.41) | (30.90) | (13.36) | 17.38 |
| Tax | 10.90 | 0.27 | (0.45) | (5.29) | (0.34) | (4.66) | (3.13) | 4.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,686 | 1,518 | 1,791 | 1,667 | 1,540 | 1,240 | 1,106 |
| Revenue growth | +11.1% | -15.2% | +7.5% | +8.3% | +24.1% | +12.1% | - |
| Other income | 33.10 | 19.48 | 28.24 | 2.33 | 2.32 | 3.11 | 2.43 |
| Total expenses | 1,535 | 1,390 | 1,541 | 1,382 | 1,213 | 1,017 | 983 |
| Employee cost | 394 | 369 | 351 | 321 | 295 | 273 | 255 |
| EBITDA | 151 | 128 | 250 | 285 | 327 | 224 | 123 |
| EBITDA margin | +9.0% | +8.4% | +14.0% | +17.1% | +21.2% | +18.0% | +11.2% |
| Depreciation | 107 | 98.25 | 87.98 | 70.60 | 78.95 | 73.12 | 70.81 |
| Interest | 88.50 | 56.63 | 36.81 | 25.03 | 14.14 | 22.22 | 26.25 |
| Profit before tax | (11.46) | (7.36) | 153 | 192 | 236 | 131 | 28.70 |
| Tax | (5.81) | 1.36 | 36.58 | 50.23 | 81.71 | 38.95 | 4.46 |
| Net profit | (3.07) | (10.08) | 108 | 142 | 155 | 92.56 | 24.43 |
| Net profit margin | -0.2% | -0.7% | +6.0% | +8.5% | +10.1% | +7.5% | +2.2% |
| EPS (₹) | (0.61) | (0.95) | 12.65 | 15.34 | 16.77 | 10.03 | 2.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 18.46 | 18.45 | 18.44 | 18.43 | 18.43 | 18.43 | 18.43 |
| Reserves & surplus | 1,081 | 1,085 | 1,108 | 1,009 | 886 | 750 | 662 |
| Shareholders' funds (net worth) | 1,099 | 1,103 | 1,127 | 1,027 | 904 | 769 | 680 |
| Secured loans | 522 | 508 | 328 | 267 | 177 | 165 | 184 |
| Unsecured loans | 238 | 246 | 186 | 66.14 | 79.87 | 93.44 | 77.54 |
| Total debt | 760 | 754 | 514 | 333 | 257 | 258 | 262 |
| Total liabilities | 1,904 | 1,904 | 1,686 | 1,401 | 1,200 | 1,069 | 978 |
| Assets | |||||||
| Gross block | 1,851 | 1,666 | 1,555 | 1,406 | 1,236 | 1,178 | 1,127 |
| Net block | 851 | 754 | 732 | 661 | 555 | 570 | 590 |
| Capital work in progress | 85.21 | 226 | 114 | 113 | 122 | 68.10 | 50.70 |
| Investments | 160 | 51.96 | 59.20 | 19.90 | 2.46 | 2.45 | 2.45 |
| Inventories | 322 | 363 | 310 | 326 | 311 | 238 | 208 |
| Sundry debtors | 541 | 374 | 408 | 351 | 297 | 234 | 209 |
| Cash & bank balances | 20.00 | 12.03 | 16.94 | 12.40 | 19.21 | 14.05 | 37.65 |
| Loans & advances | 231 | 190 | 158 | 122 | 146 | 136 | 107 |
| Total current assets | 1,114 | 939 | 893 | 811 | 773 | 622 | 562 |
| Total current liabilities | 460 | 288 | 265 | 253 | 277 | 247 | 294 |
| Net working capital | 654 | 651 | 628 | 559 | 496 | 375 | 267 |
| Total assets | 1,904 | 1,904 | 1,686 | 1,401 | 1,200 | 1,069 | 978 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 7.06 | 7.47 | 9.99 | 16.90 | 9.13 | 23.48 | 20.72 |
| Net cash from operating activities | 226 | 107 | 177 | 179 | 174 | 82.17 | 123 |
| Net cash from investing activities | (87.38) | (276) | (302) | (209) | (121) | (66.70) | (55.95) |
| Net cash from financing activities | (133) | 169 | 122 | 22.81 | (44.37) | (29.83) | (63.95) |
| Net change in cash | 5.87 | (0.41) | (2.52) | (6.91) | 7.77 | (14.35) | 2.76 |
| Closing cash | 20.00 | 12.03 | 16.94 | 12.40 | 19.21 | 14.05 | 37.65 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +11.1% | -15.2% | +7.5% | +8.3% | +24.1% | +12.1% | - |
| EBITDA growth | +17.8% | -48.7% | -12.3% | -12.9% | +46.3% | +81.3% | - |
| PBT growth | -55.7% | - | -20.0% | -18.9% | +79.9% | +357.6% | +9998.0% |
| Net income growth | +69.5% | -109.3% | -24.0% | -8.1% | +67.3% | +278.9% | - |
| Revenue CAGR (3Y) | +0.4% | -0.5% | +13.0% | +14.7% | +16.7% | +6.1% | +1.0% |
| EBITDA CAGR (3Y) | -19.1% | -26.8% | +3.8% | +32.2% | +62.1% | +18.4% | -7.7% |
| Profitability & leverage | |||||||
| Net income margin | -0.3% | -0.6% | +6.5% | +8.5% | +10.0% | +7.5% | +2.2% |
| Return on capital employed | +4.2% | +2.7% | +12.3% | +16.7% | +22.1% | +15.0% | +5.6% |
| Return on net worth | -0.3% | -0.9% | +10.8% | +14.6% | +18.5% | +12.8% | +3.6% |
| Debt / equity | 0.69 | 0.57 | 0.39 | 0.31 | 0.31 | 0.36 | 0.42 |
| Long-term debt / equity | 0.31 | 0.25 | 0.19 | 0.14 | 0.12 | 0.13 | 0.17 |
| Interest cover | 201.41 | 190.10 | 22.75 | 11.68 | 5.70 | 14.77 | 49.98 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.96 | 0.94 | 1.21 | 1.26 | 1.28 | 1.08 | 1.07 |
| Inventory turnover | 4.93 | 4.51 | 5.63 | 5.24 | 5.62 | 5.56 | 5.65 |
| Debtors turnover | 3.68 | 3.88 | 4.72 | 5.15 | 5.80 | 5.60 | 5.48 |
| EPS (₹) | (0.61) | (0.95) | 12.65 | 15.34 | 16.77 | 10.03 | 2.63 |
| Dividend per share (₹) | 0.20 | 0.20 | 1.50 | 2.25 | 2.25 | 1.50 | 0.30 |
| Book value per share (₹) | 119.08 | 119.61 | 122.22 | 111.45 | 98.13 | 83.44 | 73.81 |
Competitors of AnaCipher CRO
AnaCipher CRO has 10 listed competitors in our database, 3 of them funded. They include BioAgilytix, Alderley Analytical, Tentamus, Nordic Bioscience and Advion, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bioagilytix.com | 2008 | Durham, United States | – | 446 | Large-molecule bioanalysis is provided for biologics and biosimilars development. | |
| alderleyanalytical.com | 2013 | Stockport, United Kingdom | $869,352 | 41 | Bioanalytical assays for drug development are developed and validated. | |
| tentamus.com | 2011 | Berlin, Germany | – | 368 | Analytical and quality assurance services are provided for diverse industries. | |
| nordicbioscience.com | 1996 | Herlev, Denmark | – | 178 | Preclinical and clinical drug development CRO with proprietary in-house Biomarker platform | |
| advion.com | 1993 | Ithaca, United States | $45.64M | 54 | Microfluidics and mass spectrometry products are provided for clinical research. | |
| solvias.com | 1999 | Kaiseraugst, Switzerland | – | – | Integrated R&D services are provided for pharmaceuticals and allied sectors. | |
| eag.com | 1978 | San Diego, United States | – | 601 | Company offering a suite of scientific services for materials, engineering, agri, and life science industries | |
| synexagroup.com | 2003 | Cape Town, South Africa | – | – | Provider of comprehensive analytical and advisory services, specializing in biomarker services | |
| lightcast.bio | 2019 | Cambridge, United Kingdom | $107.09M | 25 | Advanced single-cell analysis solutions are provided for biotechnology research. | |
| apocell.com | 2004 | Houston, United States | – | 2,198 | Provider of clinical trial and clinical development on bioanalytical services |
Detailed competitors of AnaCipher CRO
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Food Regulatory Bodies
10 companies that operate in the same segment as AnaCipher CRO (Food Regulatory Bodies), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Interstate communications are regulated by this U.S. agency. | 1934 | Washington, District Of Columbia, United States | – | – | – | |
Hotel management and support services are provided in India. | 1985 | Chennai, Tamil Nadu, India | – | USD 67.36 M | 4,530 | |
Provides analytical testing and research services for global pharmaceutical industry. | 2019 | Hyderabad, Telangana, India | – | USD 16.01 M | 368 | |
Fortified atta is marketed by Fortify Health to government sectors. | 2017 | Delhi, Delhi, India | – | USD 9.57 K | – | |
Sustainable livelihoods and environmental protection for farmers are promoted. | 1983 | Oakland, California, United States | – | – | – | |
Dairy products are distributed by Australian Dairy Farmers nationwide. | 1942 | Melbourne, Victoria, Australia | – | – | – | |
Offers pharmacovigilance, regulatory, evidence evaluation, and technology solutions to pharma firms. | 2018 | Chandigarh, India | – | – | 424 | |
Manufactures pharmaceutical drugs and provides infrastructure for production in India. | 2010 | Visakhapatnam, Andhra Pradesh, India | – | USD 15.76 M | 324 | |
Provides online tools, checklists, and news on food safety standards. | 2019 | Ahmedabad, Gujarat, India | – | USD 62.48 K | – | |
Regulatory services for food compliance are provided to businesses. | 1988 | Vermontville, Michigan, United States | – | – | 42 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anacipher Cro
Complete news archive for AnaCipher CRO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AnaCipher CRO
AnaCipher CRO was founded in 2016.
AnaCipher CRO is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
AnaCipher CRO has 6,460 employees.
The primary company behind AnaCipher CRO, Indoco Remedies Limited, reported revenue of ₹1,670 Cr for FY 2025, down 9% year on year.
AnaCipher Clinical Research Organization, a division of Indoco Remedies Ltd., specializes in services like bioavailability, bioequivalence studies, regulatory approvals, medical writing, and pharmacovigilance. Based in Hyderabad, India, it supports bio-pharmaceutical companies in drug development through advanced facilities and trained researchers. The organization has executed over 625 studies and maintains strong regulatory compliance, partnering with various pharmaceutical firms to bring therapies to market efficiently.
AnaCipher CRO's top competitors include Alderley Analytical, BioAgilytix and Lightcast Discovery.
AnaCipher CRO offers Bioequivalence Studies, Regulatory Services, Medical Writing, and Pharmacovigilance Services.
Yes, AnaCipher CRO is publicly traded on NSE under the ticker symbol INDOCO.
AnaCipher CRO operates through Indoco Remedies Limited.
The legal entities of AnaCipher CRO currently have 9 directors, including Suresh Govind Kare, Sundeep Vasant Bambolkar, Aditi Milind Panandikar and others.